Trial Profile

Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OPL-0401 (Primary)
Indications Diabetic macular oedema; Diabetic retinopathy
Focus Therapeutic Use
Acronyms Spectra
Sponsors Valo Health

Most Recent Events

31 Dec 2024 Primary endpoint (Improvement in Diabetic Retinopathy Severity Scale (DRSS) score) has not been met, according to the results published in the Valo Health media release.
31 Dec 2024 Results published in the Valo Health Media Release.
14 Jun 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Aug 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com